SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.
在骨髓增生性肿瘤的临床前模型中，SHP2 抑制剂作为单一疗法以及与 JAK2 抑制剂联合使用均显示出疗效
期刊:American Journal of Hematology
影响因子:9.9
doi:10.1002/ajh.27282
Pandey Garima, Mazzacurati Lucia, Rowsell Tegan M, Horvat Nathan P, Amin Narmin E, Zhang Guolin, Akuffo Afua A, Colin-Leitzinger Christelle M, Haura Eric B, Kuykendall Andrew T, Zhang Ling, Epling-Burnette Pearlie K, Reuther Gary W
